Qiagen Says Expanded PCR IP Portfolio Will Boost Hardware and Consumables Sales, Drive Entry into IVD Market | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen's acquisition last week of additional PCR licenses from Roche and Idaho Technology will bolster the company's PCR business on several fronts, including hardware, consumables, and in vitro diagnostics, according to a company official.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.